Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib - Lung Cancer
Early Alectinib Resistance From MET Amplification in ALK Rearranged NSCLC: Response to Crizotinib with Re-response to Alectinib and Crizotinib - Clinical Lung Cancer
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation | bioRxiv
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target - ScienceDirect
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. - Abstract - Europe PMC
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
DISSECT platform with multi-omics data and various analytic tools - CNGBdb
Figure 6 from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer | Semantic Scholar
MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.,Cancer Science - X-MOL
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exo | LCTT
MET amplification increases the metastatic spread of EGFR-mutated NSCLC - Lung Cancer
FISH analysis of de novo MET amplification in advanced NSCLC and... | Download Scientific Diagram
new-molecular-drivers-in-nsclc-the-role-of-met
Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Populatio | OTT
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Journal of Thoracic Oncology
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
